Evaluation of the safety and efficacy of the Optimizer™ II and III systems with active fixation leads in subjects with heart failure resulting from systolic dysfunction
| ISRCTN | ISRCTN16213127 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN16213127 |
| Secondary identifying numbers | ID 2001-12 |
- Submission date
- 12/07/2006
- Registration date
- 20/07/2006
- Last edited
- 29/10/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Not provided at time of registration
Contact information
Prof Martin Borggrefe
Scientific
Scientific
Klinikum Mannheim GmbH
Universitätsklinikum
Fakultät für Klinische Medizin Mannheim der Universität Heidelberg
Theodor-Kutzer-Ufer 1-3
Mannheim
68167
Germany
Study information
| Study design | Multicenter, randomised, double-blind, crossover trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study acronym | FIX-CHF-4 |
| Study hypothesis | Cardiac contractility modulation (CCM) signals delivered by the Optimizer™ system will improve exercise tolerance and quality of life in subjects with heart failure resulting from systolic dysfunction. |
| Ethics approval(s) | Ethics Committees of all participating sites (15) in five countries (Germany, Italy, Netherlands, France, Czech Republic) approved the study; all competent authorities have been notified. The first ethics committee approval was received on 18/03/2002 from Allgemeines Krankenhaus Wien (AKH) Hospital, Vienna, Austria. |
| Condition | Heart failure |
| Intervention | Intravenous application of three leads to the heart through the subclavian or cephalic veins, creation of subcoutaneous pocket and implantation of a pulse generator. All patients are implanted and then randomised to either on or off for the first three months, then they crossover. |
| Intervention type | Other |
| Primary outcome measure | Co-primary efficacy endpoints: 1. Change in quality of life as assessed by Minnesota Living With Heart Failure Questionnaire (MLWHFQ) 2. Change in exercise tolerance as measured by peak oxygen consumption determined during cardiopulmonary stress test |
| Secondary outcome measures | Co-secondary efficacy endpoints: 1. Change in exercise tolerance as assessed by six minutes hall walk 2. Change in left ventricular function as assessed by echocardiography 3. Change in heart failure class as assessed by the New York Heart Association classification |
| Overall study start date | 24/05/2002 |
| Overall study end date | 31/12/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 250 |
| Participant inclusion criteria | 1. Age - subjects who are 18 years of age or older 2. Gender - subjects who are either male or female 3. Condition: 3.1. Subjects with moderate to severe heart failure as evidenced by a baseline peak oxygen uptake between 10 and 20 ml O2/min/kg 3.2. Subjects with baseline ejection fraction of 35% or less by echocardiography 3.3. Subjects who are on optimal medical therapy for heart failure, consisting of the appropriate medications, doses and duration of treatment based on standard of care for the institution. Guidelines for defining optimal medical therapy and minimum durations of treatment may vary among participating centers. However, the following set of guidelines regarding minimum duration of treatment shall be required for each class of drugs: 3.3.1. Diuretics - sufficient dose for at least two weeks so that the subject is clinically euvolemic 3.3.2. Angiotensin converting enzyme (ACE)-inhibitor or angiotensin II receptor blocker at a stable dose for at least two weeks 3.3.3. Digoxin for at least two weeks 4. Beta-blocker: 4.1. If the subject is already taking a beta-blocker, he or she must have reached the clinically indicated target dose (i.e. no further dose titration) and must have been on a stable dose for a minimum of two weeks 4.2. If the subject is not already taking a beta-blocker, the subject and the referring physician must agree that a beta-blocker will not be started until the subject completes the six-month follow-up visit of the study 5. Subjects may have an implanted pacemaker. Subjects may have an implantable cardioverter defibrillator (ICD) system with true or dedicated bipolar sensing. Subjects may have dual chamber pacemakers and dual chamber ICDs as long as the device was implanted a minimum of one month prior to enrollment. Subjects who have a documented history of non-sustained ventricular tachycardia or unexplained syncope shall be required to have evidence of non-inducibility on clinical electrophysiologic testing or have an implanted cardiac defibrillator (ICD). 6. Subjects who are otherwise eligible to participate in the study may undergo Optimizer™ pulse generator implantation at the same time as an ICD and/or pacemaker, but if the ICD or pacemaker is a dual chamber device, the Optimizer™ pulse generator cannot be activated for one month 7. Subjects who are willing and able to return for all follow-up visits |
| Participant exclusion criteria | 1. Subjects with a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease 2. Subjects with evidence of active ischemia consisting of, for example, angina or electrocardiogram (ECG) changes during exercise testing) 3. Subjects who have been hospitalized within one month prior to enrolment for heart failure, which has required the use of intravenous diuretics or inotropic support 4. Subjects without an ICD who have a documented history of sustained ventricular tachycardia (VT), or who have an indication for and ICD and are not scheduled for ICD implantation 5. Subjects with an ICD who have had appropriate ICD firing during the past one month 6. Subjects who have a clinically significant amount of ambient ectopy, defined as more than a total of 8,900 premature ventricular contractions (PVCs) per 24 hours on baseline Holter monitoring 7. Subjects with chronic atrial fibrillation or chronic atrial flutter 8. Subjects whose exercise tolerance is limited by a condition other than heart failure (e.g. angina, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, orthopedic or rheumatologic conditions) 9. Subjects who are unable to participate in a six-minute walk and/or a cardiopulmonary stress test 10. Subjects who are scheduled for a coronary artery bypass grafting (CABG) or a percutaneous transluminal coronary angioplasty (PTCA) procedure, or who have undergone a CABG procedure within three months or a PTCA procedure within one month of enrolment 11. Subjects who, in the opinion of the principal investigator, have a clinical indication for bi-ventricular pacing 12. Subjects with a left ventricular pacing lead 13. Subjects who have had a myocardial infarction within three months of study enrolment 14. Subjects with mechanical tricuspid or aortic valves 15. Subjects with a prior heart transplant 16. Subjects already having an optimizer™ device 17. Subjects with a previously implanted ICD which employs unipolar or integrated bipolar sensing 18. Subjects who are participating in another experimental protocol 19. Subjects in vulnerable populations who are unable to provide informed consent |
| Recruitment start date | 24/05/2002 |
| Recruitment end date | 31/12/2005 |
Locations
Countries of recruitment
- Czech Republic
- France
- Germany
- Italy
- Netherlands
Study participating centre
Klinikum Mannheim GmbH
Mannheim
68167
Germany
68167
Germany
Sponsor information
Impulse Dynamics Inc. (USA)
Industry
Industry
30 Ramland Road South
Suite 103
Orangeburg
10962-2698
United States of America
| Phone | +1 845 359 2389 |
|---|---|
| yaell@impulse-dynamics.com | |
| Website | http://www.impulse-dynamics.com |
"ROR" |
https://ror.org/028p2b938 |
Funders
Funder type
Industry
Impulse Dynamics Inc. (USA)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/04/2008 | Yes | No |
